AVAX Technologies (AVXT) Announces Collaboration With The University of Pennsylvania Health System Applying Its AC Vaccine Technology To The Treatment Of Non-Small Cell Lung Cancer
10/19/2005 5:12:48 PM
PHILADELPHIA--(BUSINESS WIRE)--Feb. 22, 2005--
AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announced that it has established a research collaboration with Dr. Joseph Friedberg, Chief of the Division of Thoracic Surgery at Presbyterian Medical Center, part of the University of Pennsylvania Health System, to conduct a clinical trial of its AC Vaccine in patients with non-small cell lung cancer (NSCLC). Presbyterian Medical Center and Hospital of the University of Pennsylvania, both part of the University of Pennsylvania Health System, will be the exclusive partner and clinical sites for the trial. AVAX and the University plan to submit an Investigational New Drug application (IND) for the treatment of patients with Stage I or II NSCLC to the U.S. Food and Drug Administration by March 31, 2005. The AC Vaccine consists of autologous, lung cancer cells from each patient modified with the hapten, dinitrophenyl (DNP).
The laboratory work leading to the development of the new lung cancer vaccine will be the subject of a presentation to be made at a special conference sponsored by the American Association for Cancer Research, entitled, "Molecular Pathogenesis of Lung Cancer: Opportunities for Translation to the Clinic." The conference will be held in San Diego from February 23-27.
comments powered by